MECHELEN, BELGIUM--(Marketwire - February 07, 2011) -
Galapagos NV (Euronext: GLPG) announced
today that it has been awarded a EUR2.7 million grant from the Flemish
Innovation by Science and Technology (IWT) to progress its proprietary
drug discovery research programs.
The two-year IWT-funded project focuses on progressing novel mode-of-action
small molecules that have shown antiviral activity in laboratory models,
the goal to deliver a first preclinical candidate within one year.
will collaborate on this project with the research group of Professor Johan
Neyts at the Rega Institute for Medical Research at the KU Leuven, which
long-standing expertise in developing novel strategies to treat viral
These antiviral programs focus on blocking the activity of a protein in the
human body that is essential for a number of important pathogenic viruses
carry out their own reproduction. The compounds have demonstrated potent
antiviral activity against a wide variety of normal and resistant strains.
key priorities for this project are to advance compounds against human
rhinovirus (HRV), the virus that causes the common cold, and hepatitis C
"Galapagos is once again breaking new ground with these novel antiviral
compounds that target host proteins," said Graham Dixon, SVP Drug Discovery
Galapagos. "This grant provides funding for us to further understand the
mechanism by which these orally available, small molecules play a role in
inhibiting viral infection."
About Galapagos antiviral drug discovery
In addition to its anti-infectives alliance with GlaxoSmithKline, Galapagos
progressing two proprietary antiviral programs. These small molecule
focus on host (human) targets and thereby show activity across a broad
viruses in laboratory studies. Galapagos' lead antiviral program is
in lead optimization, with plans to deliver a preclinical candidate by the
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company
specialized in the discovery and development of small molecule and antibody
therapies with novel modes-of-action. The Company is progressing one of
largest pipelines in biotech, with seven clinical and over 50 small
discovery/pre-clinical programs. Through risk/reward-sharing alliances
GlaxoSmithKline, Lilly, Janssen Pharmaceutica, Roche and Servier, Galapagos
eligible to receive up to EUR2.5 billion in downstream milestones, plus
royalties. The Galapagos Group has over 800 employees and operates
in seven countries, with global headquarters in Mechelen, Belgium. More
Cautionary note regarding forward-looking statements
This release may contain forward-looking statements, including, without
limitation, statements containing the words "believes," "anticipates,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
and "continues," as well as similar expressions. Such forward-looking
statements may involve known and unknown risks, uncertainties and other
which might cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially different
any historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking statements.
these uncertainties, the reader is advised not to place any undue reliance
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly disclaims
obligation to update any such forward-looking statements in this document
reflect any change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE